Collaborations & Alliances

Sanofi, Alnylam Restructure RNAi Therapeutics Alliance

Sanofi will obtain global development and commercialization rights to fitusiran

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi and Alnylam Pharmaceuticals, Inc. are restructuring their RNAi therapeutics alliance in an effort to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases.   Sanofi will obtain global development and commercialization rights to fitusiran, an investigational RNAi therapeutic currently in development for the treatment hemophilia A and B. Upon approval, Sanofi Genzyme will be responsible for global commercialization of fitu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters